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The hemodynamic effects of exogenously administered
arginine vasopressin were assessed in 11 patients with
chronic congestive heart failure. Infusion rates of 0.1 to
0.8 pmol/kg per min increased plasma arginine vaso-
pressin from 6.5 ± 2.7 (SD) pg/ml at control to 63 ±
39 pg/ml at the highest infusion rate. There were pro-
gressive decreases in cardiac output and stroke volume,
with increases in systemic vascular resistance and pul-
monary capillary wedge pressure, but only minimal
changes in heart rate and blood pressure. Changes in
cardiac output, stroke volume and systemic resistance
were evident from the first infusion rate, which increased
plasma arginine vasopressin from 6.5 ± 2.7 to 9.9 ±
4.6 pg/ml. A paired analysis of baseline hemodynamic
data with those measured during infusions producing an
arginine vasopressin level averaging 15 ± 2.6 pg/ml
yielded the following changes: cardiac output decreased
from 4.6 ± 1.2 to 4.2 ± 0.96 liters/min (p < 0.01),
Arginine vasopressin, the human antidiuretic hormone, is a
potent vasoconstrictor (l). Numerous studies (2-5) in the
past several years have clearly demonstrated that it exerts
important vascular effects at physiologic levels both in nor-
mal animals and in animals under a variety of types of stress .
We have been interested in a possible role for arginine
vasopressin in the vasoconstriction of human congestive
heart failure because this condition frequently is character-
ized by elevated peripheral vascular resistance and activa-
tion of other neuroendocrine vasoconstricting systems (6,7) .
We (8) and others (9-12) have now shown that plasma
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stroke volume decreased from 60 ± 19 to 54 ± 16 ml
(p < 0.005) and systemic vascular resistance increased
from 1,329 ± 396 to 1,443 ± 395 dynes-s-cm f (p =
0.01).
Thus, small increases in circulating arginine vaso-
pressin cause modest but significant adverse circulatory
effects in patients with congestive heart failure. A fall
in cardiac output , probably as a result of increased af-
terload, is seen at levels of arginine vasopressin within
the basal range found in congestive heart failure. These
data demonstrate that circulating arginine vasopressin
in physiologic concentrations is capable of influencing
hemodynamics in patients with congestive heart failure
and suggest that therapy for this condition directed at
inhibition of the vascular effect of arginine vasopressin
may be potentially useful.
(1 Am Call Cardiol 1986;8:779-83)
arginine vasopressin levels tend either to be increased or to
be inadequately suppressed for the prevailing plasma os-
molality in patients with heart failure. The current study
was performed to address the issue of whether physiolog-
ically relevant concentrations of plasma arginine vasopressin
can exert important hemodynamic effects in patients with
this condition.
Methods
Study patients. Eleven patients with chronic congestive
heart failure (New York Heart Association functional classes
II to IV) formed the study group for this investigation. All
were receiving digitalis and diuretic drugs and most had
been treated with vasodilating drugs. Patients were always
studied in a stable clinical state with diuretics and vasodi-
lators discontinued at least 12 hours in advance. The pa-
tients' ages ranged from 20 to 74 years (mean 53); 10 were
men , Three had ischemic cardiomyopathy documented by
a history of myocardial infarction or coronary angiography,
and eight had idiopathic dilated cardiomyopathy. All had
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well documented depressed ventricular function by angio-
graphic, echocardiographic or radionuclide studies.
Protocol. After giving informedconsent, all patientshad
a Swan-Ganz catheter inserted through either the median
basilic or femoral vein. A short cannula was also placed in
a brachialor femoral artery. At least 30 minuteswas allowed
to pass before baseline hemodynamic measurements were
begun. These were repeated at 5 minute intervals and, if
stable for at least two determinations, were accepted as
basal. Blood was then drawn for plasma arginine vaso-
pressin analysis and placed immediately into chilled tubes.
An infusion of synthetic arginine vasopressin (Pitressin,
Roche Pharmaceuticals) was then begun at 0.1 pmol/kg per
min. The infusion was prepared by mixing 10 units of Pi-
tressin in 250 cc of 5% dextrose in distilled water. Four
microdrops per minute provided the starting infusion rate
for an average-sized subject. The infusion was maintained
for 10 minutes, after which hemodynamic measurements
were repeated and blood was drawn again for arginine va-
sopressin determination. The infusion rate was then in-
creased to 0.2, 0.4 and 0.8 pmol/kg per min with hemo-
dynamics assessed and blood samples taken at each infusion
rate as during the first infusion rate. No subject experienced
any reactions during the study or was aware of any clinical
changes.
Data analysis. Data were analyzed by analysis of var-
iance for repeated measures on the same elements. If sig-
nificant variation was observed, the data from each infusion
rate were compared with control data using a paired { test
with Bonferroni's correction. Because of wide standard de-
viations for the actual arginine vasopressin levels achieved
during the infusions, particularly at the last two infusion
rates, a paired analysis was also carried out for each variable
at the control level and at the infusion rate producingplasma
arginine vasopressinlevels between 10and 20 pg/ml in each
individual subject. This procedure was followed because
our primary objective was to establish whether levels of
arginine vasopressin within the range observed for basal
values in heart failure were capable of exerting hemody-
namic effects in this condition.
Plasma was separated by cold centrifugation within 2
hoursafter blood sampling and immediately frozen at - 20°C
for later analysis. Samples were always extracted and ana-
lyzed within 60 days. Analysis was carried out as previously
described by a sensitive and specific radioimmunoassay (13).
Current inter- and intraassay coefficients of variation av-
erage approximately 8%.
Results
The basal argmme vasopressin level in this group of
patients was 6.4 ± 2.7 (SD) pg/rnl, which is higher than
our average normal value of 4.7 ± 2.4 pg/ml in middle-
aged subjects but lower than the mean level of 9.5 ± 4.1
pg/ml we previously reported in a larger group of patients
with heart failure.
Hemodynamic results. Figure I plots the results for
each hemodynamic variable at each infusion rate. The cor-
respondingarginine vasopressin levels (pg/ml) achieved for
each infusion rate were as follows: 0.1 pmol/kg per min,
9.9 ± 4.6; 0.2 pmol/kg per min, 18.3 ± 10; 0.4 pmol/kg
per min, 34.6 ± 24; and 0.8 pmol/kg per min, 63 ± 39.
During the infusion, heart rate and blood pressure did not
change except for a small increase in blood pressure at the
highest rate. Cardiac output (liters/min) declined from 4.6
± 1.2 to 4.2 ± 1.3 (p = 0.012) during the first infusion
period, was relatively stable at 4.1 ± 1.1 during the second
period and declined further (p < 0.0 I) during the last two
infusion periods (to 3.8 ± 0.9) . Stroke volume (ml) de-
clined from 60 ± 19 to 55 ± 20 (p = 0.02) at the first
infusion rate, remained relatively stable (54 ± 17) at the
second and declined further (p < 0.0 I) to 51 ± 17 at the
higher rates. Systemic vascular resistance (dynes-s-cm- 5)
increased from 1,329 ± 397 at control to I,445 ± 440 (p
= 0.012) during the first infusion rate, was again stable
during the second infusionrate (I ,457 ± 390) and increased
further to 1,524 ± 452 and 1,578 ± 477 during the final
infusion periods. There was significant overall variation (p
< 0.0 I) in the pulmonary wedgepressures, but no individual
pairs attained statistical significance with the corrected {
tests. There was no change in right atrial pressure and pul-
monary artery pressure remained stable.
As discussed, because of some variability in the actual
arginine vasopressin levels achieved at each rate, we also
analyzed in a paired fashion the control data and those from
the arginine vasopressin infusion rate producing a plasma
level of between 10 and 20 pg/rnl (mean 15 ± 2.6). In-
dividual responses from this analysis are shown in Figure
2. There were small but significant increases in systemic
vascular resistance (1,329 ± 396 to 1,443 ± 395
dyness-cm " ", p < 0.01), decreases in cardiac output (4.5
± 1.2 to 4.2 ± 0.9 liters/min, p < 0.01) and decreases in
stroke volume (60 ± 19 to 54 ± 16 ml, p < 0.001). The
increase in pulmonary capillary wedge pressure (22 ± 6.9
to 23 ± 6.3 mm Hg) was not statistically significant. Heart
rate and blood pressure were unchanged.
Discussion
Adverse hemodynamic effects of increased plasma ar-
ginine vasopressin. The data from this study demonstrate
adversecirculatoryeffects from increases in plasma arginine
vasopressin in patients with congestive heart failure. In-
spectionof the data from the two lowest infusionrates shows
that adverse effects occurred with very small increases in
argininevasopressinover baseline. Analysisof baselinedata
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Figure 1. Overall hemodynamic re-
sponses to arginine vasopressin infu-
sions. Data are shown as mean ± SD
for each infusion rate. See text for the
arginine vasopressin levels corre-
sponding to the infusion rate. "p <
0.05; *p < 0.01. CO = cardiac output
(liters/min); HR heart rate
(beats/min); MAP = mean arterial
pressure (mm Hg); PCWP = pul-
monary capillary wedge pressure (mm
Hg); SV = stroke volume (ml); SVR
systemic vascular resistance
(dynes-s-cm-5).
C .1 .2 .4 .1
(pMI ••"'kl"'·fn)
C .1 .2 .4 .1
(pllOl ••"'kl"'Mfn)
C .1 .2 .4 .1
(pMI ••AI"'·fn)
and those during an arginine vasopressin level between 10
and 20 pg/ml in all subjects confirmed these effects (Fig.
2). The major hemodynamic changes seen were a decrease
in cardiac output due entirely to a fall in stroke volume and
an increase in systemic vascular resistance. Arginine va-
sopressin is not thought to exert major primary effects on
myocardial function (14); hence, although we cannot ex-
clude direct cardiodepression, the deterioration in cardiac
output was probably a consequence of the enhanced sen-
sitivity of the abnormal ventricle to peripheral vasoconstric-
tion. There were also smaller but still consistent increases
in the pulmonary capillary wedge pressure. We cannot ex-
clude an effect due to coronary vasoconstriction with im-
paired left ventricular function secondary to ischemia, but
most of the patients had no known coronary artery disease,
none reported chest discomfort and the changes in pulmo-
nary capillary wedge pressure were quite modest. These
factors, plus the absence of heart rate and blood pressure
changes, argue against ischemia-induced cardiodepression
and in favor of a decrease in function secondary to afterload
stress alone or in combination with direct cardiodepression.
Neurohumoral effects of arginine vasopressin. Argi-
nine vasopressin is a potent direct vasoconstrictor (I) and
also may potentiate the vasoconstricting effects of norepi-
nephrine and angiotensin II (15,16). We did not measure
norepinephrine and renin levels in these patients, but be-
cause these neurohumoral controllers are also frequently
increased in patients with heart failure (6,7), some of the
vasoconstricting effects of arginine vasopressin seen in this
study could have been a result of an interaction of arginine
vasopressin with these other neurohumoral mediators. Such
potentiating effects have been observed in animals with
changes in arginine vasopressin as small as 1 pg/ml ( 15, 16).
Therefore, very small changes in plasma arginine vaso-
pressin, even if not exerting independent effects, may be
important in a milieu of overall increases in neurohumoral
activity coupled with extreme sensitivity of ventricular func-
tion to afterload stress such as is found in congestive heart
failure. Further study to examine the interactions of arginine
vasopressin, norepinephrine and angiotensin II seems war-
ranted in patients with this disease.
Effect on cardiac output. As noted, the decrease in
cardiac output in these patients was due to a fall in stroke
volume, heart rate having remained stable. Cardiac output
does fall in normal animals given small amounts of arginine
vasopressin, but the fall is due almost entirely to a decrease
in heart rate caused by an interaction between arginine va-
sopressin and the sinoaortic baroreceptors (14). Similar data
have been reported in preliminary form in normal humans,
albeit with noninvasive cardiac output determinations (17).
The observation of depressed cardiac output during low level
arginine vasopressin infusions may therefore not be unique
to congestive failure, but the mechanism is different, be-
cause in heart failure the decreased output occurs indepen-
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dent of heart rate . The lack of heart rate depression in
conges tive failure could be a result of blunted sinoao rtic
baroreceptor function in this condition.
Potential limitations. We believe that the hemodynamic
changes observed in this investigation are not likely to have
been due to factors other than the arginine vasopressin in-
fusions. Hemodynamic variables were stable before the in-
fusio n, volumes of fluid administered were very small, no
subjec t reported adverse reacti ons and the absence of heart
rate and blood pressure changes argues aga inst any spon-
taneous stress -induced cardiovascular impairment. It has
also recentl y been observed that the hemodynam ic status
spontaneously impro ves, rather than worsens, after right
heart catheteriza tion without further interve ntion in conges-
tive heart failure ( 18), so it is possible that we may even
have underestimated the effec ts of vasopress in. Finally. we
should note that the respon ses to arginine vaso pressin were
remarkably consistent despite a fairly wide range of baseline
hemodynamics (Fig. 2). Given these considerations, we
believe we were in fact observing the effec ts of the arginine
vasopress in infusion and not those of chance or other vari-
ables .
Clinical implications. A clear implication of our study
is the possibility that arginine vasopressi n may participate
in the vasoconstriction of congestive heart failure. Our data
do not permit speculation about the role of arginine vaso-
pressin in the baseline vasoconstriction of congestive heart
failure , because we cannot extrapolate from the effects of
an increase in circulating arg inine vasopress in to the basal
state. However, we have show n that very small increases
in arginine vaso press in over basel ine (fro m 6.4 ± 2.7 to
as little as 9.9 ± 4 .0 and 18.3 ± 10 pg/ml ) (Fig. I) can
exert definite , if modest , hemodynamic effects . Most cur-
rent studies on arginine vaso pressi n in heart failure have
been performed under basal conditions in stable patient s,
whereas few data are avail able concerning arginine vaso-
pressin levels during clini cal decompensation or osmotic
stimulation in heart failure . Eleven patients in our original
series had arginine vasopressi n levels between 10 and 20
pg/rnl , and two had levels over 20 pg/ml. Riegger et al.
( 19) recently reported on a group of sicker patient s in whom
plasma arginine vasopressi n averaged ove r 40 pg/ml. Ar-
ginine vaso pressin increases markedl y (to levels of 80 pg/rnl
or more) during hypotension in norm al subjects (20) . We
have reported that arginine vaso pressi n is stimulated by
acute furosemide administration in heart failure (2 1) and
Uretsky et al. (12) reported striking increases in arginine
vasopress in durin g osmotic stimulation in patient s with heart
failure . Hence , it is clear that the levels produced dur ing
our infusion study are well within the observable range in
clinica l conges tive heart failure .
Therapeutic implications. To fully clarify the role of
arginine vasopress in in the vasoconstriction of congestive
heart failure, studies with selective inhibitors of the vascular
effects of arginine vasopressin are needed, under both nor-
mal and stressed conditions. Relatively selective blockers
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of the "VI" or vascular receptor for arginine vasopressin
are now available (22). The first report in subjects with heart
failure demonstrated no effect of such a blocker if arginine
vasopressin levels were normal, but a dramatic vasodilating
response in one subject with high arginine vasopressin levels
(23). A second report (24) using this compound indicates
possible partial agonist effects at low arginine vasopressin
levels yet demonstrated vasodilation in three subjects with
increased levels. The infusion data from our study therefore
complement these preliminary inhibitor trials by demon-
strating vasoconstricting effects of modest increases in ar-
ginine vasopressin in congestive heart failure. On the basis
of all current data, we believe that continued evaluation of
arginine vasopressin blockade in patients with congestive
heart failure may be warranted. It is possible, with the renin-
angiotensin system and converting enzyme inhibition as a
precedent, that targeted therapy at arginine vasopressin-me-
diated vasoconstriction might prove to be another step in
the rational design of specific vasodilator therapy for some
patients with this disease.
We thank Susan Ziesche, Vicki Garberg and Donna Dodge for help in
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and Belinda Anderson for preparing the manuscript.
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